Emanuel and Miller argue that “by themselves the payment and profit status of [TeGenero] do not make the [TGN1412] trail ethically suspect” (2007, 76). I think that they are right to argue that there is nothing necessarily incriminating about for-profit companies conducting medical research, but that this conclusion is irrelevant to the moral status of incentives in the TeGenero trial. Not only...
